BioNTech continues to rise by around 8.5% and reaches a $11 billion authorization agreement with Pfizer.

BioNTech continued to rise by approximately 8.5%, reaching $122.7. The stock surged by over 18% yesterday. In terms of news, Pfizer announced a licensing agreement with BioNTech for the new generation anti-cancer drug BNT327, with milestone payments in the agreement totaling up to $11.1 billion. Additionally, Truist Securities has raised BioNTech's target price from $151 to $155 and maintains a "buy" rating.